<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43150">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544607</url>
  </required_header>
  <id_info>
    <org_study_id>2015P001912</org_study_id>
    <nct_id>NCT02544607</nct_id>
  </id_info>
  <brief_title>Ketamine for Depression: An MRI Study</brief_title>
  <official_title>Baseline Insular Dysfunction as a Predictor of Ketamine's Antidepressant Effects in Anxious Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brain &amp; Behavior Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease
      has been shown to last for up to one month. MRI technology will be used before and after
      ketamine for patients with depression to examine the extent to which certain brain areas
      predict ketamine's antidepressant effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketamine's antidepressant effects were measured with Hamilton Depression Rating Scale (HDRS)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding Ended.
  </why_stopped>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>4 hours</time_frame>
    <description>Depression rating scale; possible scores range from 0 to 81 with higher scores indicating higher depression symptoms</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Depression</condition>
  <condition>Anxious Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible participants will receive open label ketamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine 0.5mg/kg over 40 minutes IV</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketamine Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients with Depression

        Patients will:

          1. be 18-64 years old,

          2. read, understand, and provide written informed consent in English,

          3. meet criteria for a primary psychiatric diagnosis of major depressive disorder for ≥
             4 weeks,

          4. have a history of ≥1 failed medication trial during the current depression

          5. be on a stable antidepressant and psychotherapy regimen for ≥28 days,

          6. maintain a treating doctor who is in agreement with study participation,

          7. have a reliable chaperone accompany them home following the completion of the
             ketamine infusion day,

          8. be generally healthy, as assessed by medical history, physical examination (including
             vital signs), clinical laboratory evaluations, and electrocardiogram (EKG),

          9. be of non-childbearing potential or use of an acceptable form of birth control
             (females only),

         10. be right handed.

        Exclusion Criteria: Patients with Depression

        Patients will be excluded if any of the following criteria are met:

        1) delirium or dementia diagnosis, 2) unstable medical illness or clinically significant
        laboratory results, 3) history of clinically significant cardiovascular disease or
        electrocardiogram (EKG) findings, or medical conditions that put the patient at risk for
        possible cardiac side effects or alter brain morphology (e.g., traumatic brain injury), 4)
        history of multiple adverse drug reactions, 5) current/past history of psychotic
        disorders, 6) active substance use disorders (except nicotine and caffeine) within the
        past six months or past history of ketamine/PCP abuse, 7) requirement of excluded
        medications that may interact with ketamine, 8) weigh &gt;250 lbs., 9) pregnancy,
        breastfeeding, or unacceptable means of birth control (females only) 10) presence of MRI
        contraindications (e.g., presence of metallic (ferromagnetic) implants (e.g., heart
        pacemaker, aneurysm clips)), 11) current serious suicidal or homicidal risk, or 12)
        concurrent participation in other research studies.

        Inclusion Criteria: Healthy Controls

        Healthy Controls will:

          1. be 18-64 years old,

          2. read, understand, and provide written informed consent in English,

          3. have a reliable chaperone accompany them home following the completion of the
             ketamine infusion day,

          4. be generally healthy, as assessed by medical history, physical examination (including
             vital signs), clinical laboratory evaluations, and electrocardiogram (EKG),

          5. be of non-childbearing potential or use of an acceptable form of birth control
             (females only), and

          6. be right handed.

        Exclusion Criteria: Healthy Controls

        Healthy controls will be excluded if any of the following criteria are met:

          1. current or past psychiatric diagnosis (excluding phobias), including alcohol or
             substance abuse or dependence diagnosis (except for nicotine or caffeine),

          2. presence of MRI contraindications (e.g., presence of metallic (ferromagnetic)
             implants (e.g., heart pacemaker, aneurysm clips)),

          3. presence of medical illness likely to alter brain morphology and/or physiology (e.g.,
             traumatic brain injury),

          4. requirement of excluded medications that may interact with ketamine,

          5. presence of psychiatric disorders in first-degree relatives,

          6. pregnancy, breastfeeding, or unacceptable means of birth control (females only), or

          7. weight &gt;250 lbs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Ionescu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.depressionmgh.org/our-studies</url>
    <description>MGH Depression Clinical and Research Program</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 8, 2017</lastchanged_date>
  <firstreceived_date>September 4, 2015</firstreceived_date>
  <firstreceived_results_date>March 2, 2017</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Dawn F Ionescu</investigator_full_name>
    <investigator_title>Assistant in Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Depression</keyword>
  <keyword>Anxious Depression</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>Ketamine: Ketamine 0.5mg/kg over 40 minutes IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Didn't meet I/E criteria</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients who signed consent for the study and had a screening visit</population>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>Ketamine: Ketamine 0.5mg/kg over 40 minutes IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" lower_limit="19" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDRS Total Score</title>
          <population>Only participants who passed the screening visit and went onto the active study phase were analyzed for baseline depression scores.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.7" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale (HDRS)</title>
        <description>Depression rating scale; possible scores range from 0 to 81 with higher scores indicating higher depression symptoms</description>
        <time_frame>4 hours</time_frame>
        <population>HDRS at 4 hours post-ketamine</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine: Ketamine 0.5mg/kg over 40 minutes IV</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (HDRS)</title>
          <description>Depression rating scale; possible scores range from 0 to 81 with higher scores indicating higher depression symptoms</description>
          <population>HDRS at 4 hours post-ketamine</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Ketamine: Ketamine 0.5mg/kg over 40 minutes IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sarah White, Director, Quality Improvement Program</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-278-1130</phone>
      <email>swhite12@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
